Gelesis

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, January 2, 2024
Gelesis, Alimera Sciences, Bookkeeping, CFO, Physician, International, Elon University, Growth, Patient, Compensated emancipation, Therapy, Employment, Retina, Trosia

“Elliot joins the Alimera leadership team at an exciting time as we enter 2024 preparing to enhance our growth trajectory and drive improved cash flow,” said Rick Eiswirth, Alimera’s President and CEO.

Key Points: 
  • “Elliot joins the Alimera leadership team at an exciting time as we enter 2024 preparing to enhance our growth trajectory and drive improved cash flow,” said Rick Eiswirth, Alimera’s President and CEO.
  • Most recently he was the Chief Financial Officer with Orgenesis, Inc., a publicly traded global biotech company transforming the processing of cell and gene therapies.
  • At Gelesis, Mr. Maltz advanced from Corporate Controller to Vice President of Finance and then to Chief Financial Officer while leading numerous operational and fundraising initiatives.
  • The Inducement Option is an inducement material to Mr. Maltz entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Cell Reports Medicine Publication Demonstrates How Gelesis’ Oral Therapeutic Hydrogel Promotes Weight Loss and Metabolic Health by Targeting the Gut-Liver Axis in Pre-Clinical Studies

Retrieved on: 
Tuesday, October 17, 2023
Research, FDA, Diabetes, Fitness & Nutrition, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Paper, Sugar, Multimedia, Gel, DSM-IV codes, OSH, Doctor of Philosophy, Obesity, Hydrogel, Prevalence, Weight loss, Gelesis, Diet-induced obesity model, Metabolic syndrome, Humanitas University, Inulin, NASH, Psyllium, Liver disease, Fatty liver disease, Growth, NAFLD, Dietary supplement, Akkermansia

The reported studies examined both the efficacy and mechanism of action of Gelesis’ oral superabsorbent hydrogels (OSH) in preclinical models of diet-induced obesity, metabolic syndrome, and NASH.

Key Points: 
  • The reported studies examined both the efficacy and mechanism of action of Gelesis’ oral superabsorbent hydrogels (OSH) in preclinical models of diet-induced obesity, metabolic syndrome, and NASH.
  • The Gelesis OSH consistently resulted in weight loss, improved insulin sensitivity, and prevented the progression of NAFLD.
  • The study also demonstrated that the beneficial metabolic effects were independent of the weight loss effect.
  • “Our work shows the potential of oral superabsorbent hydrogels to be an effective and non-invasive therapeutic tool in the long-term treatment of obesity and metabolic disorders.”

PureTech Health plc – Half-Year Report

Retrieved on: 
Tuesday, August 29, 2023
Infectious Diseases, Neurology, Clinical Trials, Stem Cells, Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Clostridioides difficile infection, Plan, Central nervous system, Depression, Psychosis, University, Fragile X-associated tremor/ataxia syndrome, U.S. Department of Defense Strategy for Operating in Cyberspace, Gel, Engineering, Classification, Schizophrenia, Food allergy, Anxiety, ADHD, University of California, Davis, PureTech Health, Fast Track, Attention, CNS, Attention deficit hyperactivity disorder predominantly inattentive, AML, Investigational New Drug, Patient, Investment, KRTX, Variometer, Ageing, KarXT, FDA, IPF, Safety, Vaccine, Pharmaceutical industry, Dietary supplement, Cryptocurrency, Vedanta, Gelesis, Yolo Akili, FXTAS

Awarded up to $11.4 million from the U.S. Department of Defense to advance LYT-300 for Fragile X-associated Tremor/ Ataxia Syndrome (FXTAS).

Key Points: 
  • Awarded up to $11.4 million from the U.S. Department of Defense to advance LYT-300 for Fragile X-associated Tremor/ Ataxia Syndrome (FXTAS).
  • Akili subsequently released EndeavorOTC,10 a video game treatment to improve attention in adults 18 years and older with ADHD, available without a prescription.
  • Gelesis and PureTech have entered into an Agreement and Plan of Merger, subject to agreed upon terms and conditions.
  • PureTech has also entered into an Agreement and Plan of Merger to purchase all of the outstanding stock of Gelesis and take the company private.

Gelesis Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Tuesday, March 28, 2023
Biotechnology, Pharmaceutical, Alternative Medicine, General Health, Health, Vitamins, Supplements, Fitness & Nutrition, Other Health, Table, Classification, Marketing, Disclosure, Patient, Comment, OTC, Webcast, Adjustment, FDA, Safety, Cryptocurrency, Video game, Bookkeeping, Security (finance), Gelesis100, Gelesis

We acquired 121,500 new members during 2022 compared to 61,400 new members during 2021, a 98% increase year-over-year, and sold 374,000 units in 2022 compared to 174,000 units in 2021, a 115% increase.

Key Points: 
  • We acquired 121,500 new members during 2022 compared to 61,400 new members during 2021, a 98% increase year-over-year, and sold 374,000 units in 2022 compared to 174,000 units in 2021, a 115% increase.
  • Net loss was $(55.8) million and Adjusted EBITDA was $(83.3) million in 2022, compared to net loss of $(93.3) million and Adjusted EBITDA of $(73.8) million in 2021.
  • The Company may issue an additional $5.0 million to this shareholder upon mutual acceptance of Gelesis meeting certain conditions.
  • A pre-recorded webcast discussing these results is available on the “Events & Presentations” section of the Gelesis Investor Relations website at https://ir.gelesis.com/ .

Gelesis to Participate in the 25th Annual ICR Conference

Retrieved on: 
Thursday, January 5, 2023
FDA, General Health, Pharmaceutical, Health, GLS, Conference, NYSE, Multimedia, FDA, Webcast, Gelesis, Hydrogel

Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023.

Key Points: 
  • Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230105005182/en/
    Gelesis is the maker of Plenity, an FDA-cleared weight management product.
  • The live webcast can be accessed on the “Events & Presentations” section of the Gelesis Investor Relations website at https://ir.gelesis.com/ .

Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

Retrieved on: 
Monday, November 7, 2022
General Health, Fitness & Nutrition, Health, Other Health, Patient, Gel, Company, Exercise, Diet, Multimedia, Obesity, Cellulose, FDA, Functional constipation, NASH, Type 2 diabetes, NYSE, Webcast, Incidence, Abdomen, Gelesis, Allergy, GLS, Pain scale, Nature, Flatulence, BMI, Food, Use, Non-alcoholic fatty liver disease, Citric acid, Body mass index, Diarrhea, NAFLD, Absorption, Defecation, Gelatin, Human, Dietary supplement, Hydrogel

Gelesis Holdings, Inc. (NYSE:GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open.

Key Points: 
  • Gelesis Holdings, Inc. (NYSE:GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open.
  • Gelesis management will host a live conference call and webcast at 8:30 a.m.
  • View the full release here: https://www.businesswire.com/news/home/20221107005166/en/
    Gelesis is a consumer-centered biotherapeutics company and the maker of Plenity for weight management.
  • (Photo: Business Wire)
    The live call can be accessed via webcast on the Events & Presentations section of the Gelesis Investor Relations website at https://ir.gelesis.com/ .

Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit

Retrieved on: 
Thursday, September 8, 2022
Fitness & Nutrition, Health, Other Health, Functional constipation, COVID-19, Security (finance), Citric acid, Food, Flatulence, Diarrhea, Pain scale, BMI, NYSE, Gel, Obesity, Perception, NAFLD, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Exercise, Abdomen, Allergy, Cellulose, XXV, 100,000, Incidence, Forward-looking statement, GLS, Diet, U.S. Securities and Exchange Commission, Defecation, New, Absorption, Body mass index, Patient, Use, Social media, FDA, Company, NASH, Twitter, Human, Type 2 diabetes, Failure, Chief commercial officer, Risk, Webcast, Non-alcoholic fatty liver disease, Intellectual property, Annual report, Gelatin, Growth, Industry, Social conditioning, Nature, Dietary supplement, Risk management, Gelesis, Hydrogel

Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and Commercial Officer, will participate in the Jefferies Virtual Fitness & Wellness Summit on Monday, September 12, 2022.

Key Points: 
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and Commercial Officer, will participate in the Jefferies Virtual Fitness & Wellness Summit on Monday, September 12, 2022.
  • The live webcast can be accessed on the Events & Presentations section of the Gelesis Investor Relations website at https://ir.gelesis.com/ .
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.
  • Gelesis gives no assurance that any expectations set forth in this press release will be achieved.

Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET

Retrieved on: 
Wednesday, August 17, 2022
Alternative Medicine, FDA, Health, General Health, Pharmaceutical, Biotechnology, FDA, Allergy, Social conditioning, Intellectual property, U.S. Securities and Exchange Commission, Defecation, Exercise, Risk, Abdomen, Diet, Obesity, Industry, XXV, NYSE, Human, Forward-looking statement, 100,000, GLS, Failure, Growth, Incidence, Absorption, Security (finance), Annual report, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Perception, New, Pain scale, Chief commercial officer, Gel, Patient, NASH, Gelatin, COVID-19, Company, Type 2 diabetes, Twitter, Non-alcoholic fatty liver disease, Cellulose, Food, Use, NAFLD, Citric acid, Nature, Functional constipation, Social media, Webcast, Flatulence, Body mass index, IPO, Diarrhea, BMI, Dietary supplement, Risk management, Hydrogel, Gelesis

Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat with IPO Edge today at 2:00 PM ET.

Key Points: 
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat with IPO Edge today at 2:00 PM ET.
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.
  • Our first-of-their-kind non-systemic superabsorbent hydrogels are made entirely from naturally derived building blocks.
  • Gelesis gives no assurance that any expectations set forth in this press release will be achieved.

Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022

Retrieved on: 
Thursday, August 4, 2022
Alternative Medicine, General Health, Pharmaceutical, Health, FDA, Allergy, Liver, BMI, Defecation, Exercise, Risk, Abdomen, Diet, Obesity, Forward-looking statement, Human, NYSE, Failure, GLS, Growth, SEC, COVID, COVID 19, Incidence, Absorption, Xi, Environment, New, Pain scale, Gel, Patient, NASH, Gelatin, Use, Company, Type 2 diabetes, Twitter, Non-alcoholic fatty liver disease, Cellulose, Food, NAFLD, Citric acid, 100,000, Nature, Functional constipation, Webcast, Flatulence, Body mass index, Diarrhea, Ix, Adoption, Dietary supplement, Risk management, Nitenpyram, Hydrogel, Gelesis

Gelesis Holdings, Inc. (NYSE:GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that the Company will report financial results for the Second Quarter ended June 30, 2022, on August 15, 2022 prior to the market open.

Key Points: 
  • Gelesis Holdings, Inc. (NYSE:GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that the Company will report financial results for the Second Quarter ended June 30, 2022, on August 15, 2022 prior to the market open.
  • The live call can be accessed via webcast on the Events & Presentations section of the Gelesis Investor Relations website at https://ir.gelesis.com/ .
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.
  • These filings address other important risks and uncertainties that could cause actual results and events to differ materially from those contained in the forward-looking statements.

League Adds Industry Leadership to Advisory Board with New Member, Promotion

Retrieved on: 
Tuesday, May 24, 2022
Health, General Health, Twilio, MBA, COO, Providence Health & Services, Leadership, Solution, Welsh, Platform as a service, Association, American Association of Neuromuscular & Electrodiagnostic Medicine, Research, Man, Butler, Technology, EVP, Providence, Faculty, Population health, Love, CMO, American Association, Stowe, CFO, MD, CEO, Pharmaceutical industry, Management, Service, Walgreens, League, Gelesis

League , the leading healthcare consumer experience platform, today announced changes to its advisory board that involve two healthcare industry veterans.

Key Points: 
  • League , the leading healthcare consumer experience platform, today announced changes to its advisory board that involve two healthcare industry veterans.
  • Harry Leider, MD, MBA, a former Walgreens executive and current chief medical officer and executive vice president of Gelesis, will join the advisory board as a new member.
  • A healthcare operating partner at Welsh, Carson, Anderson and Stowe who formerly led Providence Health and Services, Butler joined Leagues advisory board in 2021.
  • Dr. Leider is a current faculty member and former president and chairman of the board at the American Association for Physician Leadership.